Vaccine Trials

There's one curretly going on at Johns Hopkins:

J1112: A FEASIBILITY AND TOXICITY STUDY OF A GM-CSF SECRETING ALLOGENEIC MELANOMA VACCINE (MELANOMA GVAX) ADMINISTERED ALONE OR IN COMBINATION WITH CYCLOPHOSPHAMIDE IN SUBJECTS WITH SURGICALLY RESECTED AT-RISK MELANOMA
This melanoma vaccine trial is a phase I study for patients with stage IIB, IIC, III or IV melanoma who have undergone complete surgical resection but who are at risk for developing recurrence of their disease.  Melanoma GVAX is an investigational vaccine designed to teach the immune system to recognize and eliminate melanoma tumors, which may persist at a microscopic level after surgery.  In this study, some patients will receive Melanoma GVAX alone (low dose or high dose), while others will receive Melanoma GVAX plus low-dose cyclophosphamide. Cyclophosphamide is a chemotherapy frequently used in cancer treatment.  In this study, it will be given at a low dose to try to augment the effects of the vaccine.  The purpose of this study is to find the optimal dose of Melanoma GVAX, with or without cyclophosphamide, that is safe and that produces an immune response.  The vaccine will be given in the skin monthly for four doses.  Eligible patients must be ≥18 years old with melanoma arising in the skin or mucous membranes (such as the nostrils, mouth, or rectum) that has been completely resected at least 2 weeks but no more than 6 months prior to receiving the first treatment on this trial.  Patients with melanomas arising in the eye (ocular) are not eligible.  Participants must not have hepatitis, HIV, or any history of an immune disorder.  Patients must not have received any type of cancer immunotherapy, such as interleukin-2, interferon alfa or other melanoma vaccines.  Patients will be evaluated on this trial for 6 months and then followed yearly for 5 years.

If you're interested in this trial, here is the contact information:

The Johns Hopkins Melanoma Program
10753 Falls Road
Hopkins Pavilion II, Suite 415
Lutherville, MD 21093
(410) 616-7660 phone
(410) 616-7663 fax

There's one curretly going on at Johns Hopkins:

J1112: A FEASIBILITY AND TOXICITY STUDY OF A GM-CSF SECRETING ALLOGENEIC MELANOMA VACCINE (MELANOMA GVAX) ADMINISTERED ALONE OR IN COMBINATION WITH CYCLOPHOSPHAMIDE IN SUBJECTS WITH SURGICALLY RESECTED AT-RISK MELANOMA
This melanoma vaccine trial is a phase I study for patients with stage IIB, IIC, III or IV melanoma who have undergone complete surgical resection but who are at risk for developing recurrence of their disease.  Melanoma GVAX is an investigational vaccine designed to teach the immune system to recognize and eliminate melanoma tumors, which may persist at a microscopic level after surgery.  In this study, some patients will receive Melanoma GVAX alone (low dose or high dose), while others will receive Melanoma GVAX plus low-dose cyclophosphamide. Cyclophosphamide is a chemotherapy frequently used in cancer treatment.  In this study, it will be given at a low dose to try to augment the effects of the vaccine.  The purpose of this study is to find the optimal dose of Melanoma GVAX, with or without cyclophosphamide, that is safe and that produces an immune response.  The vaccine will be given in the skin monthly for four doses.  Eligible patients must be ≥18 years old with melanoma arising in the skin or mucous membranes (such as the nostrils, mouth, or rectum) that has been completely resected at least 2 weeks but no more than 6 months prior to receiving the first treatment on this trial.  Patients with melanomas arising in the eye (ocular) are not eligible.  Participants must not have hepatitis, HIV, or any history of an immune disorder.  Patients must not have received any type of cancer immunotherapy, such as interleukin-2, interferon alfa or other melanoma vaccines.  Patients will be evaluated on this trial for 6 months and then followed yearly for 5 years.

If you're interested in this trial, here is the contact information:

The Johns Hopkins Melanoma Program
10753 Falls Road
Hopkins Pavilion II, Suite 415
Lutherville, MD 21093
(410) 616-7660 phone
(410) 616-7663 fax

There's one curretly going on at Johns Hopkins:

J1112: A FEASIBILITY AND TOXICITY STUDY OF A GM-CSF SECRETING ALLOGENEIC MELANOMA VACCINE (MELANOMA GVAX) ADMINISTERED ALONE OR IN COMBINATION WITH CYCLOPHOSPHAMIDE IN SUBJECTS WITH SURGICALLY RESECTED AT-RISK MELANOMA
This melanoma vaccine trial is a phase I study for patients with stage IIB, IIC, III or IV melanoma who have undergone complete surgical resection but who are at risk for developing recurrence of their disease.  Melanoma GVAX is an investigational vaccine designed to teach the immune system to recognize and eliminate melanoma tumors, which may persist at a microscopic level after surgery.  In this study, some patients will receive Melanoma GVAX alone (low dose or high dose), while others will receive Melanoma GVAX plus low-dose cyclophosphamide. Cyclophosphamide is a chemotherapy frequently used in cancer treatment.  In this study, it will be given at a low dose to try to augment the effects of the vaccine.  The purpose of this study is to find the optimal dose of Melanoma GVAX, with or without cyclophosphamide, that is safe and that produces an immune response.  The vaccine will be given in the skin monthly for four doses.  Eligible patients must be ≥18 years old with melanoma arising in the skin or mucous membranes (such as the nostrils, mouth, or rectum) that has been completely resected at least 2 weeks but no more than 6 months prior to receiving the first treatment on this trial.  Patients with melanomas arising in the eye (ocular) are not eligible.  Participants must not have hepatitis, HIV, or any history of an immune disorder.  Patients must not have received any type of cancer immunotherapy, such as interleukin-2, interferon alfa or other melanoma vaccines.  Patients will be evaluated on this trial for 6 months and then followed yearly for 5 years.

If you're interested in this trial, here is the contact information:

The Johns Hopkins Melanoma Program
10753 Falls Road
Hopkins Pavilion II, Suite 415
Lutherville, MD 21093
(410) 616-7660 phone
(410) 616-7663 fax

http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=10679987        

Link to vaccine trials…

http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=10679987        

Link to vaccine trials…

http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=10679987        

Link to vaccine trials…